10/570159 IAP9 Rectification 01 MAR 2006

Docket No.: 0152-0725PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Noboru FUKUDA et al.

Application No.: NEW

Confirmation No.: N/A

Filed: March 1, 2006

Art Unit: N/A

For: TGF-β GENE EXPRESSION INHIBITOR

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.

US Publication No. 2004/209254 corresponds to WO Patent No. 02/08468. US Publication No. 2004/171799 corresponds to WO Patent No. 03/00683.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or Birch, Stewart, Kolasch & Birch, LLP

GMM/smt

10/570159 IAP9 Recd PCT/PTO 01 MAR 2006

Application No.: NEW Docket No.: 0152-0725PUS1

submitted to the Office in a prior application number PCT/JP2004/012854, filed

September 3, 2004

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 1, 2006

Respectfully submitted,

Gerald M. Murphy, Jr.

Registration No. 28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

2

Attorney for Applicant

10/570159 LAPORCE OFFIND 01 MAR 2015

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/E	3/PTO		Complete if Known		
				Application Number	NEW	
11	IFORMATIC	DN DIS	SCLOSURE	Filing Date	March 1, 2006	
S	TATEMENT	iby A	PPLICANT	First Named Inventor	Noboru FUKUDA	
				Art Unit	N/A	
	(Use as many	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0152-0725PUS1	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20040209254-A1	10-21-2004	Henderson	
	AB*	US-20040171799-A1	09-02-2004	Sugiyama et al.	

		FOREI	GN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA**	WO-02/08468-A1	01-31-2002			
	BB**	WO-03/00683-A1	01-03-2003			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with an double asterisk (*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check match between the patent of the paten mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	FUKUDA, N., Gene therapy for arterial proliferative disease and progressive renal diseases by nucleic acid medicines, Nichidai Igaku Zasshi, July 2003, vol. 62, no. 7, pages 329 to 336, particularly, page 335, left column	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date			
loiensture l		Date	Examiner
Signature		Considered	Signature

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.